nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulfamethoxazole—NAT1—urinary bladder cancer	0.513	0.761	CbGaD
Sulfamethoxazole—NAT2—urinary bladder cancer	0.161	0.239	CbGaD
Sulfamethoxazole—PTGS1—Etoposide—urinary bladder cancer	0.0201	0.172	CbGbCtD
Sulfamethoxazole—ALB—Fluorouracil—urinary bladder cancer	0.0179	0.154	CbGbCtD
Sulfamethoxazole—CYP3A4—Thiotepa—urinary bladder cancer	0.0173	0.149	CbGbCtD
Sulfamethoxazole—CYP2C8—Fluorouracil—urinary bladder cancer	0.0139	0.119	CbGbCtD
Sulfamethoxazole—CYP2C8—Etoposide—urinary bladder cancer	0.0116	0.0994	CbGbCtD
Sulfamethoxazole—NAT2—urine—urinary bladder cancer	0.0113	0.293	CbGeAlD
Sulfamethoxazole—ALB—Methotrexate—urinary bladder cancer	0.0099	0.085	CbGbCtD
Sulfamethoxazole—CYP2C9—Fluorouracil—urinary bladder cancer	0.00967	0.0831	CbGbCtD
Sulfamethoxazole—CYP2C9—Cisplatin—urinary bladder cancer	0.00822	0.0706	CbGbCtD
Sulfamethoxazole—CYP3A4—Etoposide—urinary bladder cancer	0.0047	0.0403	CbGbCtD
Sulfamethoxazole—NAT1—prostate gland—urinary bladder cancer	0.00368	0.0958	CbGeAlD
Sulfamethoxazole—CYP3A4—Doxorubicin—urinary bladder cancer	0.0032	0.0275	CbGbCtD
Sulfamethoxazole—NAT1—seminal vesicle—urinary bladder cancer	0.00312	0.0811	CbGeAlD
Sulfamethoxazole—NAT2—renal system—urinary bladder cancer	0.00276	0.0718	CbGeAlD
Sulfamethoxazole—NAT1—urethra—urinary bladder cancer	0.00247	0.0642	CbGeAlD
Sulfamethoxazole—NAT1—female reproductive system—urinary bladder cancer	0.00201	0.0523	CbGeAlD
Sulfamethoxazole—NAT1—vagina—urinary bladder cancer	0.00182	0.0473	CbGeAlD
Sulfamethoxazole—CYP2C9—urine—urinary bladder cancer	0.00175	0.0456	CbGeAlD
Sulfamethoxazole—UGT1A9—renal system—urinary bladder cancer	0.00149	0.0388	CbGeAlD
Sulfamethoxazole—CYP3A4—urine—urinary bladder cancer	0.00134	0.0348	CbGeAlD
Sulfamethoxazole—NAT1—lymph node—urinary bladder cancer	0.00118	0.0306	CbGeAlD
Sulfamethoxazole—PTGS1—prostate gland—urinary bladder cancer	0.000575	0.015	CbGeAlD
Sulfamethoxazole—Dapsone—NAT2—urinary bladder cancer	0.000526	0.606	CrCbGaD
Sulfamethoxazole—PTGS1—seminal vesicle—urinary bladder cancer	0.000486	0.0127	CbGeAlD
Sulfamethoxazole—CYP2C8—renal system—urinary bladder cancer	0.000483	0.0126	CbGeAlD
Sulfamethoxazole—PTGS1—epithelium—urinary bladder cancer	0.000423	0.011	CbGeAlD
Sulfamethoxazole—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000407	0.0106	CbGeAlD
Sulfamethoxazole—PTGS1—renal system—urinary bladder cancer	0.000392	0.0102	CbGeAlD
Sulfamethoxazole—CYP2C8—female reproductive system—urinary bladder cancer	0.000387	0.0101	CbGeAlD
Sulfamethoxazole—CYP2C8—vagina—urinary bladder cancer	0.00035	0.00911	CbGeAlD
Sulfamethoxazole—CYP2C9—female reproductive system—urinary bladder cancer	0.000344	0.00894	CbGeAlD
Sulfamethoxazole—CYP3A4—renal system—urinary bladder cancer	0.000327	0.00852	CbGeAlD
Sulfamethoxazole—ALB—lymph node—urinary bladder cancer	0.000322	0.00838	CbGeAlD
Sulfamethoxazole—PTGS1—female reproductive system—urinary bladder cancer	0.000314	0.00817	CbGeAlD
Sulfamethoxazole—PTGS1—vagina—urinary bladder cancer	0.000284	0.00739	CbGeAlD
Sulfamethoxazole—CYP3A4—female reproductive system—urinary bladder cancer	0.000262	0.00682	CbGeAlD
Sulfamethoxazole—Dapsone—MPO—urinary bladder cancer	0.000249	0.287	CrCbGaD
Sulfamethoxazole—PTGS1—lymph node—urinary bladder cancer	0.000184	0.00478	CbGeAlD
Sulfamethoxazole—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000103	0.00143	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000102	0.00142	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000102	0.00141	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000101	0.00141	CcSEcCtD
Sulfamethoxazole—Fatigue—Gemcitabine—urinary bladder cancer	0.000101	0.00141	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Fluorouracil—urinary bladder cancer	0.0001	0.00139	CcSEcCtD
Sulfamethoxazole—Pancytopenia—Methotrexate—urinary bladder cancer	0.0001	0.00139	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Etoposide—urinary bladder cancer	0.0001	0.00139	CcSEcCtD
Sulfamethoxazole—Asthenia—Thiotepa—urinary bladder cancer	0.0001	0.00139	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	9.98e-05	0.00138	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	9.97e-05	0.00138	CcSEcCtD
Sulfamethoxazole—Ataxia—Doxorubicin—urinary bladder cancer	9.95e-05	0.00138	CcSEcCtD
Sulfamethoxazole—Neutropenia—Methotrexate—urinary bladder cancer	9.88e-05	0.00137	CcSEcCtD
Sulfamethoxazole—Pruritus—Thiotepa—urinary bladder cancer	9.88e-05	0.00137	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Etoposide—urinary bladder cancer	9.82e-05	0.00136	CcSEcCtD
Sulfamethoxazole—Eosinophilia—Epirubicin—urinary bladder cancer	9.79e-05	0.00136	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Cisplatin—urinary bladder cancer	9.76e-05	0.00135	CcSEcCtD
Sulfamethoxazole—Skin disorder—Etoposide—urinary bladder cancer	9.74e-05	0.00135	CcSEcCtD
Sulfamethoxazole—Pancreatitis—Epirubicin—urinary bladder cancer	9.69e-05	0.00134	CcSEcCtD
Sulfamethoxazole—Photosensitivity reaction—Methotrexate—urinary bladder cancer	9.64e-05	0.00134	CcSEcCtD
Sulfamethoxazole—Anorexia—Etoposide—urinary bladder cancer	9.56e-05	0.00133	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Thiotepa—urinary bladder cancer	9.55e-05	0.00133	CcSEcCtD
Sulfamethoxazole—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	9.53e-05	0.00132	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Cisplatin—urinary bladder cancer	9.52e-05	0.00132	CcSEcCtD
Sulfamethoxazole—Pneumonia—Methotrexate—urinary bladder cancer	9.48e-05	0.00131	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	9.45e-05	0.00131	CcSEcCtD
Sulfamethoxazole—Infestation NOS—Methotrexate—urinary bladder cancer	9.42e-05	0.00131	CcSEcCtD
Sulfamethoxazole—Infestation—Methotrexate—urinary bladder cancer	9.42e-05	0.00131	CcSEcCtD
Sulfamethoxazole—Depression—Methotrexate—urinary bladder cancer	9.39e-05	0.0013	CcSEcCtD
Sulfamethoxazole—Pancytopenia—Epirubicin—urinary bladder cancer	9.39e-05	0.0013	CcSEcCtD
Sulfamethoxazole—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	9.34e-05	0.0013	CcSEcCtD
Sulfamethoxazole—Dapsone—PTGS2—urinary bladder cancer	9.33e-05	0.107	CrCbGaD
Sulfamethoxazole—Body temperature increased—Gemcitabine—urinary bladder cancer	9.29e-05	0.00129	CcSEcCtD
Sulfamethoxazole—Renal failure—Methotrexate—urinary bladder cancer	9.26e-05	0.00128	CcSEcCtD
Sulfamethoxazole—Neutropenia—Epirubicin—urinary bladder cancer	9.25e-05	0.00128	CcSEcCtD
Sulfamethoxazole—Dizziness—Thiotepa—urinary bladder cancer	9.23e-05	0.00128	CcSEcCtD
Sulfamethoxazole—Stomatitis—Methotrexate—urinary bladder cancer	9.18e-05	0.00127	CcSEcCtD
Sulfamethoxazole—Urticaria—Fluorouracil—urinary bladder cancer	9.18e-05	0.00127	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Fluorouracil—urinary bladder cancer	9.13e-05	0.00127	CcSEcCtD
Sulfamethoxazole—Eosinophilia—Doxorubicin—urinary bladder cancer	9.06e-05	0.00126	CcSEcCtD
Sulfamethoxazole—Photosensitivity reaction—Epirubicin—urinary bladder cancer	9.02e-05	0.00125	CcSEcCtD
Sulfamethoxazole—Pancreatitis—Doxorubicin—urinary bladder cancer	8.97e-05	0.00124	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Etoposide—urinary bladder cancer	8.94e-05	0.00124	CcSEcCtD
Sulfamethoxazole—Hepatobiliary disease—Methotrexate—urinary bladder cancer	8.91e-05	0.00124	CcSEcCtD
Sulfamethoxazole—Vomiting—Thiotepa—urinary bladder cancer	8.88e-05	0.00123	CcSEcCtD
Sulfamethoxazole—Pneumonia—Epirubicin—urinary bladder cancer	8.87e-05	0.00123	CcSEcCtD
Sulfamethoxazole—Infestation NOS—Epirubicin—urinary bladder cancer	8.82e-05	0.00122	CcSEcCtD
Sulfamethoxazole—Infestation—Epirubicin—urinary bladder cancer	8.82e-05	0.00122	CcSEcCtD
Sulfamethoxazole—Rash—Thiotepa—urinary bladder cancer	8.8e-05	0.00122	CcSEcCtD
Sulfamethoxazole—Dermatitis—Thiotepa—urinary bladder cancer	8.8e-05	0.00122	CcSEcCtD
Sulfamethoxazole—Agranulocytosis—Methotrexate—urinary bladder cancer	8.79e-05	0.00122	CcSEcCtD
Sulfamethoxazole—Headache—Thiotepa—urinary bladder cancer	8.75e-05	0.00121	CcSEcCtD
Sulfamethoxazole—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	8.74e-05	0.00121	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Etoposide—urinary bladder cancer	8.72e-05	0.00121	CcSEcCtD
Sulfamethoxazole—Pancytopenia—Doxorubicin—urinary bladder cancer	8.69e-05	0.00121	CcSEcCtD
Sulfamethoxazole—Renal failure—Epirubicin—urinary bladder cancer	8.67e-05	0.0012	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Etoposide—urinary bladder cancer	8.66e-05	0.0012	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Cisplatin—urinary bladder cancer	8.66e-05	0.0012	CcSEcCtD
Sulfamethoxazole—Fatigue—Etoposide—urinary bladder cancer	8.65e-05	0.0012	CcSEcCtD
Sulfamethoxazole—Neuropathy peripheral—Epirubicin—urinary bladder cancer	8.64e-05	0.0012	CcSEcCtD
Sulfamethoxazole—Stomatitis—Epirubicin—urinary bladder cancer	8.59e-05	0.00119	CcSEcCtD
Sulfamethoxazole—Neutropenia—Doxorubicin—urinary bladder cancer	8.55e-05	0.00119	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Fluorouracil—urinary bladder cancer	8.51e-05	0.00118	CcSEcCtD
Sulfamethoxazole—Hepatitis—Methotrexate—urinary bladder cancer	8.46e-05	0.00117	CcSEcCtD
Sulfamethoxazole—Asthenia—Gemcitabine—urinary bladder cancer	8.43e-05	0.00117	CcSEcCtD
Sulfamethoxazole—Urinary tract disorder—Methotrexate—urinary bladder cancer	8.35e-05	0.00116	CcSEcCtD
Sulfamethoxazole—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	8.35e-05	0.00116	CcSEcCtD
Sulfamethoxazole—Hepatobiliary disease—Epirubicin—urinary bladder cancer	8.34e-05	0.00116	CcSEcCtD
Sulfamethoxazole—Pruritus—Gemcitabine—urinary bladder cancer	8.31e-05	0.00115	CcSEcCtD
Sulfamethoxazole—Nausea—Thiotepa—urinary bladder cancer	8.29e-05	0.00115	CcSEcCtD
Sulfamethoxazole—Urethral disorder—Methotrexate—urinary bladder cancer	8.29e-05	0.00115	CcSEcCtD
Sulfamethoxazole—Agranulocytosis—Epirubicin—urinary bladder cancer	8.23e-05	0.00114	CcSEcCtD
Sulfamethoxazole—Pneumonia—Doxorubicin—urinary bladder cancer	8.2e-05	0.00114	CcSEcCtD
Sulfamethoxazole—Gastrointestinal pain—Etoposide—urinary bladder cancer	8.2e-05	0.00114	CcSEcCtD
Sulfamethoxazole—Pruritus—Fluorouracil—urinary bladder cancer	8.17e-05	0.00113	CcSEcCtD
Sulfamethoxazole—Infestation—Doxorubicin—urinary bladder cancer	8.16e-05	0.00113	CcSEcCtD
Sulfamethoxazole—Infestation NOS—Doxorubicin—urinary bladder cancer	8.16e-05	0.00113	CcSEcCtD
Sulfamethoxazole—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	8.09e-05	0.00112	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Cisplatin—urinary bladder cancer	8.07e-05	0.00112	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Gemcitabine—urinary bladder cancer	8.04e-05	0.00112	CcSEcCtD
Sulfamethoxazole—Renal failure—Doxorubicin—urinary bladder cancer	8.02e-05	0.00111	CcSEcCtD
Sulfamethoxazole—Erythema multiforme—Methotrexate—urinary bladder cancer	8e-05	0.00111	CcSEcCtD
Sulfamethoxazole—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	8e-05	0.00111	CcSEcCtD
Sulfamethoxazole—Urticaria—Etoposide—urinary bladder cancer	7.97e-05	0.00111	CcSEcCtD
Sulfamethoxazole—Stomatitis—Doxorubicin—urinary bladder cancer	7.95e-05	0.0011	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Etoposide—urinary bladder cancer	7.93e-05	0.0011	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Etoposide—urinary bladder cancer	7.93e-05	0.0011	CcSEcCtD
Sulfamethoxazole—Hepatitis—Epirubicin—urinary bladder cancer	7.91e-05	0.0011	CcSEcCtD
Sulfamethoxazole—Eye disorder—Methotrexate—urinary bladder cancer	7.9e-05	0.0011	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Fluorouracil—urinary bladder cancer	7.9e-05	0.0011	CcSEcCtD
Sulfamethoxazole—Tinnitus—Methotrexate—urinary bladder cancer	7.88e-05	0.00109	CcSEcCtD
Sulfamethoxazole—Asthenia—Cisplatin—urinary bladder cancer	7.86e-05	0.00109	CcSEcCtD
Sulfamethoxazole—Urinary tract disorder—Epirubicin—urinary bladder cancer	7.82e-05	0.00108	CcSEcCtD
Sulfamethoxazole—Connective tissue disorder—Epirubicin—urinary bladder cancer	7.78e-05	0.00108	CcSEcCtD
Sulfamethoxazole—Urethral disorder—Epirubicin—urinary bladder cancer	7.76e-05	0.00108	CcSEcCtD
Sulfamethoxazole—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	7.71e-05	0.00107	CcSEcCtD
Sulfamethoxazole—Immune system disorder—Methotrexate—urinary bladder cancer	7.64e-05	0.00106	CcSEcCtD
Sulfamethoxazole—Dizziness—Fluorouracil—urinary bladder cancer	7.64e-05	0.00106	CcSEcCtD
Sulfamethoxazole—Mediastinal disorder—Methotrexate—urinary bladder cancer	7.62e-05	0.00106	CcSEcCtD
Sulfamethoxazole—Agranulocytosis—Doxorubicin—urinary bladder cancer	7.61e-05	0.00106	CcSEcCtD
Sulfamethoxazole—Chills—Methotrexate—urinary bladder cancer	7.59e-05	0.00105	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Cisplatin—urinary bladder cancer	7.49e-05	0.00104	CcSEcCtD
Sulfamethoxazole—Erythema multiforme—Epirubicin—urinary bladder cancer	7.48e-05	0.00104	CcSEcCtD
Sulfamethoxazole—Vomiting—Gemcitabine—urinary bladder cancer	7.47e-05	0.00104	CcSEcCtD
Sulfamethoxazole—Mental disorder—Methotrexate—urinary bladder cancer	7.41e-05	0.00103	CcSEcCtD
Sulfamethoxazole—Rash—Gemcitabine—urinary bladder cancer	7.41e-05	0.00103	CcSEcCtD
Sulfamethoxazole—Dermatitis—Gemcitabine—urinary bladder cancer	7.4e-05	0.00103	CcSEcCtD
Sulfamethoxazole—Eye disorder—Epirubicin—urinary bladder cancer	7.4e-05	0.00103	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Etoposide—urinary bladder cancer	7.39e-05	0.00103	CcSEcCtD
Sulfamethoxazole—Tinnitus—Epirubicin—urinary bladder cancer	7.38e-05	0.00102	CcSEcCtD
Sulfamethoxazole—Malnutrition—Methotrexate—urinary bladder cancer	7.36e-05	0.00102	CcSEcCtD
Sulfamethoxazole—Headache—Gemcitabine—urinary bladder cancer	7.36e-05	0.00102	CcSEcCtD
Sulfamethoxazole—Vomiting—Fluorouracil—urinary bladder cancer	7.34e-05	0.00102	CcSEcCtD
Sulfamethoxazole—Hepatitis—Doxorubicin—urinary bladder cancer	7.32e-05	0.00102	CcSEcCtD
Sulfamethoxazole—Rash—Fluorouracil—urinary bladder cancer	7.28e-05	0.00101	CcSEcCtD
Sulfamethoxazole—Dermatitis—Fluorouracil—urinary bladder cancer	7.28e-05	0.00101	CcSEcCtD
Sulfamethoxazole—Headache—Fluorouracil—urinary bladder cancer	7.24e-05	0.001	CcSEcCtD
Sulfamethoxazole—Urinary tract disorder—Doxorubicin—urinary bladder cancer	7.23e-05	0.001	CcSEcCtD
Sulfamethoxazole—Asthenia—Etoposide—urinary bladder cancer	7.2e-05	0.000998	CcSEcCtD
Sulfamethoxazole—Connective tissue disorder—Doxorubicin—urinary bladder cancer	7.2e-05	0.000998	CcSEcCtD
Sulfamethoxazole—Urethral disorder—Doxorubicin—urinary bladder cancer	7.18e-05	0.000996	CcSEcCtD
Sulfamethoxazole—Immune system disorder—Epirubicin—urinary bladder cancer	7.15e-05	0.000992	CcSEcCtD
Sulfamethoxazole—Mediastinal disorder—Epirubicin—urinary bladder cancer	7.13e-05	0.00099	CcSEcCtD
Sulfamethoxazole—Chills—Epirubicin—urinary bladder cancer	7.1e-05	0.000985	CcSEcCtD
Sulfamethoxazole—Pruritus—Etoposide—urinary bladder cancer	7.1e-05	0.000985	CcSEcCtD
Sulfamethoxazole—Nausea—Gemcitabine—urinary bladder cancer	6.98e-05	0.000968	CcSEcCtD
Sulfamethoxazole—Vomiting—Cisplatin—urinary bladder cancer	6.96e-05	0.000966	CcSEcCtD
Sulfamethoxazole—Mental disorder—Epirubicin—urinary bladder cancer	6.93e-05	0.000962	CcSEcCtD
Sulfamethoxazole—Erythema multiforme—Doxorubicin—urinary bladder cancer	6.92e-05	0.000961	CcSEcCtD
Sulfamethoxazole—Rash—Cisplatin—urinary bladder cancer	6.9e-05	0.000958	CcSEcCtD
Sulfamethoxazole—Dermatitis—Cisplatin—urinary bladder cancer	6.9e-05	0.000957	CcSEcCtD
Sulfamethoxazole—Malnutrition—Epirubicin—urinary bladder cancer	6.89e-05	0.000956	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Etoposide—urinary bladder cancer	6.86e-05	0.000952	CcSEcCtD
Sulfamethoxazole—Nausea—Fluorouracil—urinary bladder cancer	6.86e-05	0.000952	CcSEcCtD
Sulfamethoxazole—Eye disorder—Doxorubicin—urinary bladder cancer	6.84e-05	0.000949	CcSEcCtD
Sulfamethoxazole—Tinnitus—Doxorubicin—urinary bladder cancer	6.83e-05	0.000947	CcSEcCtD
Sulfamethoxazole—Tension—Epirubicin—urinary bladder cancer	6.76e-05	0.000938	CcSEcCtD
Sulfamethoxazole—Nervousness—Epirubicin—urinary bladder cancer	6.69e-05	0.000928	CcSEcCtD
Sulfamethoxazole—Dizziness—Etoposide—urinary bladder cancer	6.63e-05	0.00092	CcSEcCtD
Sulfamethoxazole—Immune system disorder—Doxorubicin—urinary bladder cancer	6.61e-05	0.000918	CcSEcCtD
Sulfamethoxazole—Vertigo—Methotrexate—urinary bladder cancer	6.61e-05	0.000918	CcSEcCtD
Sulfamethoxazole—Mediastinal disorder—Doxorubicin—urinary bladder cancer	6.6e-05	0.000916	CcSEcCtD
Sulfamethoxazole—Leukopenia—Methotrexate—urinary bladder cancer	6.59e-05	0.000914	CcSEcCtD
Sulfamethoxazole—Chills—Doxorubicin—urinary bladder cancer	6.57e-05	0.000912	CcSEcCtD
Sulfamethoxazole—Nausea—Cisplatin—urinary bladder cancer	6.5e-05	0.000902	CcSEcCtD
Sulfamethoxazole—Cough—Methotrexate—urinary bladder cancer	6.42e-05	0.000891	CcSEcCtD
Sulfamethoxazole—Mental disorder—Doxorubicin—urinary bladder cancer	6.42e-05	0.00089	CcSEcCtD
Sulfamethoxazole—Convulsion—Methotrexate—urinary bladder cancer	6.38e-05	0.000885	CcSEcCtD
Sulfamethoxazole—Vomiting—Etoposide—urinary bladder cancer	6.38e-05	0.000885	CcSEcCtD
Sulfamethoxazole—Malnutrition—Doxorubicin—urinary bladder cancer	6.37e-05	0.000884	CcSEcCtD
Sulfamethoxazole—Rash—Etoposide—urinary bladder cancer	6.32e-05	0.000877	CcSEcCtD
Sulfamethoxazole—Dermatitis—Etoposide—urinary bladder cancer	6.32e-05	0.000877	CcSEcCtD
Sulfamethoxazole—Headache—Etoposide—urinary bladder cancer	6.28e-05	0.000872	CcSEcCtD
Sulfamethoxazole—Arthralgia—Methotrexate—urinary bladder cancer	6.27e-05	0.00087	CcSEcCtD
Sulfamethoxazole—Myalgia—Methotrexate—urinary bladder cancer	6.27e-05	0.00087	CcSEcCtD
Sulfamethoxazole—Tension—Doxorubicin—urinary bladder cancer	6.26e-05	0.000868	CcSEcCtD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	6.22e-05	0.000864	CcSEcCtD
Sulfamethoxazole—Nervousness—Doxorubicin—urinary bladder cancer	6.19e-05	0.000859	CcSEcCtD
Sulfamethoxazole—Vertigo—Epirubicin—urinary bladder cancer	6.19e-05	0.000859	CcSEcCtD
Sulfamethoxazole—Leukopenia—Epirubicin—urinary bladder cancer	6.17e-05	0.000856	CcSEcCtD
Sulfamethoxazole—Cough—Epirubicin—urinary bladder cancer	6.01e-05	0.000834	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Methotrexate—urinary bladder cancer	6.01e-05	0.000834	CcSEcCtD
Sulfamethoxazole—Convulsion—Epirubicin—urinary bladder cancer	5.97e-05	0.000828	CcSEcCtD
Sulfamethoxazole—Nausea—Etoposide—urinary bladder cancer	5.96e-05	0.000827	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Methotrexate—urinary bladder cancer	5.89e-05	0.000817	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Methotrexate—urinary bladder cancer	5.88e-05	0.000816	CcSEcCtD
Sulfamethoxazole—Myalgia—Epirubicin—urinary bladder cancer	5.87e-05	0.000814	CcSEcCtD
Sulfamethoxazole—Arthralgia—Epirubicin—urinary bladder cancer	5.87e-05	0.000814	CcSEcCtD
Sulfamethoxazole—Skin disorder—Methotrexate—urinary bladder cancer	5.84e-05	0.00081	CcSEcCtD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	5.82e-05	0.000808	CcSEcCtD
Sulfamethoxazole—Vertigo—Doxorubicin—urinary bladder cancer	5.73e-05	0.000795	CcSEcCtD
Sulfamethoxazole—Anorexia—Methotrexate—urinary bladder cancer	5.73e-05	0.000795	CcSEcCtD
Sulfamethoxazole—Leukopenia—Doxorubicin—urinary bladder cancer	5.71e-05	0.000792	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Epirubicin—urinary bladder cancer	5.62e-05	0.00078	CcSEcCtD
Sulfamethoxazole—Cough—Doxorubicin—urinary bladder cancer	5.56e-05	0.000772	CcSEcCtD
Sulfamethoxazole—Convulsion—Doxorubicin—urinary bladder cancer	5.52e-05	0.000766	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Epirubicin—urinary bladder cancer	5.51e-05	0.000765	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Epirubicin—urinary bladder cancer	5.51e-05	0.000764	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	5.47e-05	0.000759	CcSEcCtD
Sulfamethoxazole—Skin disorder—Epirubicin—urinary bladder cancer	5.46e-05	0.000758	CcSEcCtD
Sulfamethoxazole—Insomnia—Methotrexate—urinary bladder cancer	5.43e-05	0.000754	CcSEcCtD
Sulfamethoxazole—Myalgia—Doxorubicin—urinary bladder cancer	5.43e-05	0.000753	CcSEcCtD
Sulfamethoxazole—Arthralgia—Doxorubicin—urinary bladder cancer	5.43e-05	0.000753	CcSEcCtD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	5.39e-05	0.000748	CcSEcCtD
Sulfamethoxazole—Anorexia—Epirubicin—urinary bladder cancer	5.36e-05	0.000744	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Methotrexate—urinary bladder cancer	5.36e-05	0.000743	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Methotrexate—urinary bladder cancer	5.29e-05	0.000734	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Methotrexate—urinary bladder cancer	5.22e-05	0.000725	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Doxorubicin—urinary bladder cancer	5.2e-05	0.000722	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	5.19e-05	0.00072	CcSEcCtD
Sulfamethoxazole—Fatigue—Methotrexate—urinary bladder cancer	5.18e-05	0.000719	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	5.12e-05	0.000711	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Doxorubicin—urinary bladder cancer	5.1e-05	0.000708	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Doxorubicin—urinary bladder cancer	5.09e-05	0.000707	CcSEcCtD
Sulfamethoxazole—Insomnia—Epirubicin—urinary bladder cancer	5.09e-05	0.000706	CcSEcCtD
Sulfamethoxazole—Skin disorder—Doxorubicin—urinary bladder cancer	5.05e-05	0.000701	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Epirubicin—urinary bladder cancer	5.01e-05	0.000695	CcSEcCtD
Sulfamethoxazole—Anorexia—Doxorubicin—urinary bladder cancer	4.96e-05	0.000688	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Epirubicin—urinary bladder cancer	4.95e-05	0.000687	CcSEcCtD
Sulfamethoxazole—Gastrointestinal pain—Methotrexate—urinary bladder cancer	4.91e-05	0.000682	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Epirubicin—urinary bladder cancer	4.89e-05	0.000678	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	4.85e-05	0.000673	CcSEcCtD
Sulfamethoxazole—Fatigue—Epirubicin—urinary bladder cancer	4.85e-05	0.000673	CcSEcCtD
Sulfamethoxazole—Urticaria—Methotrexate—urinary bladder cancer	4.77e-05	0.000662	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Methotrexate—urinary bladder cancer	4.75e-05	0.000659	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Methotrexate—urinary bladder cancer	4.75e-05	0.000659	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	4.74e-05	0.000658	CcSEcCtD
Sulfamethoxazole—Insomnia—Doxorubicin—urinary bladder cancer	4.71e-05	0.000653	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Doxorubicin—urinary bladder cancer	4.64e-05	0.000644	CcSEcCtD
Sulfamethoxazole—Gastrointestinal pain—Epirubicin—urinary bladder cancer	4.6e-05	0.000638	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Doxorubicin—urinary bladder cancer	4.58e-05	0.000635	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Doxorubicin—urinary bladder cancer	4.52e-05	0.000627	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	4.49e-05	0.000623	CcSEcCtD
Sulfamethoxazole—Fatigue—Doxorubicin—urinary bladder cancer	4.49e-05	0.000622	CcSEcCtD
Sulfamethoxazole—Urticaria—Epirubicin—urinary bladder cancer	4.47e-05	0.00062	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Epirubicin—urinary bladder cancer	4.44e-05	0.000617	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Epirubicin—urinary bladder cancer	4.44e-05	0.000617	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Methotrexate—urinary bladder cancer	4.43e-05	0.000614	CcSEcCtD
Sulfamethoxazole—Asthenia—Methotrexate—urinary bladder cancer	4.31e-05	0.000598	CcSEcCtD
Sulfamethoxazole—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	4.25e-05	0.00059	CcSEcCtD
Sulfamethoxazole—Pruritus—Methotrexate—urinary bladder cancer	4.25e-05	0.00059	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Epirubicin—urinary bladder cancer	4.14e-05	0.000575	CcSEcCtD
Sulfamethoxazole—Urticaria—Doxorubicin—urinary bladder cancer	4.13e-05	0.000573	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Doxorubicin—urinary bladder cancer	4.11e-05	0.000571	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Doxorubicin—urinary bladder cancer	4.11e-05	0.000571	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Methotrexate—urinary bladder cancer	4.11e-05	0.00057	CcSEcCtD
Sulfamethoxazole—Asthenia—Epirubicin—urinary bladder cancer	4.03e-05	0.00056	CcSEcCtD
Sulfamethoxazole—Pruritus—Epirubicin—urinary bladder cancer	3.98e-05	0.000552	CcSEcCtD
Sulfamethoxazole—Dizziness—Methotrexate—urinary bladder cancer	3.97e-05	0.000551	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Epirubicin—urinary bladder cancer	3.85e-05	0.000534	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Doxorubicin—urinary bladder cancer	3.83e-05	0.000532	CcSEcCtD
Sulfamethoxazole—Vomiting—Methotrexate—urinary bladder cancer	3.82e-05	0.00053	CcSEcCtD
Sulfamethoxazole—Rash—Methotrexate—urinary bladder cancer	3.79e-05	0.000526	CcSEcCtD
Sulfamethoxazole—Dermatitis—Methotrexate—urinary bladder cancer	3.78e-05	0.000525	CcSEcCtD
Sulfamethoxazole—Headache—Methotrexate—urinary bladder cancer	3.76e-05	0.000522	CcSEcCtD
Sulfamethoxazole—Asthenia—Doxorubicin—urinary bladder cancer	3.73e-05	0.000518	CcSEcCtD
Sulfamethoxazole—Dizziness—Epirubicin—urinary bladder cancer	3.72e-05	0.000516	CcSEcCtD
Sulfamethoxazole—Pruritus—Doxorubicin—urinary bladder cancer	3.68e-05	0.000511	CcSEcCtD
Sulfamethoxazole—Vomiting—Epirubicin—urinary bladder cancer	3.57e-05	0.000496	CcSEcCtD
Sulfamethoxazole—Nausea—Methotrexate—urinary bladder cancer	3.57e-05	0.000495	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Doxorubicin—urinary bladder cancer	3.56e-05	0.000494	CcSEcCtD
Sulfamethoxazole—Rash—Epirubicin—urinary bladder cancer	3.55e-05	0.000492	CcSEcCtD
Sulfamethoxazole—Dermatitis—Epirubicin—urinary bladder cancer	3.54e-05	0.000491	CcSEcCtD
Sulfamethoxazole—Headache—Epirubicin—urinary bladder cancer	3.52e-05	0.000489	CcSEcCtD
Sulfamethoxazole—Dizziness—Doxorubicin—urinary bladder cancer	3.44e-05	0.000477	CcSEcCtD
Sulfamethoxazole—Nausea—Epirubicin—urinary bladder cancer	3.34e-05	0.000463	CcSEcCtD
Sulfamethoxazole—Vomiting—Doxorubicin—urinary bladder cancer	3.31e-05	0.000459	CcSEcCtD
Sulfamethoxazole—Rash—Doxorubicin—urinary bladder cancer	3.28e-05	0.000455	CcSEcCtD
Sulfamethoxazole—Dermatitis—Doxorubicin—urinary bladder cancer	3.28e-05	0.000455	CcSEcCtD
Sulfamethoxazole—Headache—Doxorubicin—urinary bladder cancer	3.26e-05	0.000452	CcSEcCtD
Sulfamethoxazole—Nausea—Doxorubicin—urinary bladder cancer	3.09e-05	0.000429	CcSEcCtD
Sulfamethoxazole—ALB—Folate Metabolism—IL2—urinary bladder cancer	2.8e-05	0.000286	CbGpPWpGaD
Sulfamethoxazole—NAT1—Metabolism—PTEN—urinary bladder cancer	2.77e-05	0.000283	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—UGT2B7—urinary bladder cancer	2.75e-05	0.000281	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Biological oxidations—GSTP1—urinary bladder cancer	2.72e-05	0.000278	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	2.72e-05	0.000278	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.69e-05	0.000274	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	2.68e-05	0.000274	CbGpPWpGaD
Sulfamethoxazole—NAT1—Metabolism—EP300—urinary bladder cancer	2.64e-05	0.000269	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—GSTZ1—urinary bladder cancer	2.58e-05	0.000264	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—GSTP1—urinary bladder cancer	2.54e-05	0.00026	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Selenium Micronutrient Network—TNF—urinary bladder cancer	2.52e-05	0.000257	CbGpPWpGaD
Sulfamethoxazole—ALB—Vitamin B12 Metabolism—TNF—urinary bladder cancer	2.51e-05	0.000256	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	2.5e-05	0.000256	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—CYP4B1—urinary bladder cancer	2.47e-05	0.000253	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.47e-05	0.000252	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—GSTO2—urinary bladder cancer	2.45e-05	0.00025	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—NAT1—urinary bladder cancer	2.45e-05	0.00025	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	2.43e-05	0.000248	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.41e-05	0.000246	CbGpPWpGaD
Sulfamethoxazole—ALB—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	2.4e-05	0.000245	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	2.38e-05	0.000243	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—TYMS—urinary bladder cancer	2.36e-05	0.000241	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—SLC19A1—urinary bladder cancer	2.34e-05	0.000239	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—NCOR1—urinary bladder cancer	2.34e-05	0.000239	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—GSTM1—urinary bladder cancer	2.34e-05	0.000239	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PRSS3—urinary bladder cancer	2.28e-05	0.000233	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—UGT2B7—urinary bladder cancer	2.24e-05	0.000229	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—GPX1—urinary bladder cancer	2.24e-05	0.000228	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	2.22e-05	0.000226	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—ERCC2—urinary bladder cancer	2.2e-05	0.000224	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.19e-05	0.000223	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	2.17e-05	0.000222	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	2.15e-05	0.00022	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	2.11e-05	0.000215	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—MTHFR—urinary bladder cancer	2.06e-05	0.000211	CbGpPWpGaD
Sulfamethoxazole—ALB—Folate Metabolism—TNF—urinary bladder cancer	2.04e-05	0.000208	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	2.04e-05	0.000208	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—CYP4B1—urinary bladder cancer	2.02e-05	0.000206	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.01e-05	0.000205	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	1.98e-05	0.000202	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—SLC19A1—urinary bladder cancer	1.9e-05	0.000195	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PRSS3—urinary bladder cancer	1.86e-05	0.00019	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.83e-05	0.000186	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—TYMP—urinary bladder cancer	1.82e-05	0.000186	CbGpPWpGaD
Sulfamethoxazole—ALB—Folate Metabolism—TP53—urinary bladder cancer	1.8e-05	0.000184	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.75e-05	0.000179	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—PPARG—urinary bladder cancer	1.67e-05	0.000171	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	1.67e-05	0.00017	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GSTZ1—urinary bladder cancer	1.66e-05	0.000169	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—NAT2—urinary bladder cancer	1.65e-05	0.000168	CbGpPWpGaD
Sulfamethoxazole—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	1.62e-05	0.000165	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—CREBBP—urinary bladder cancer	1.61e-05	0.000164	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	1.58e-05	0.000162	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—NAT1—urinary bladder cancer	1.58e-05	0.000162	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GSTO2—urinary bladder cancer	1.57e-05	0.000161	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—NAT1—urinary bladder cancer	1.57e-05	0.000161	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.56e-05	0.000159	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.55e-05	0.000158	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.49e-05	0.000152	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—TYMP—urinary bladder cancer	1.48e-05	0.000152	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	1.46e-05	0.000149	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	1.45e-05	0.000148	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.44e-05	0.000147	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—UGT2B7—urinary bladder cancer	1.44e-05	0.000147	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.43e-05	0.000146	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—RRM2—urinary bladder cancer	1.42e-05	0.000145	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	1.38e-05	0.000141	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	1.36e-05	0.000139	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	1.34e-05	0.000137	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—NAT2—urinary bladder cancer	1.34e-05	0.000137	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.34e-05	0.000137	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.33e-05	0.000135	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—PTGS2—urinary bladder cancer	1.32e-05	0.000135	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—ENO2—urinary bladder cancer	1.32e-05	0.000134	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—HPGDS—urinary bladder cancer	1.32e-05	0.000134	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.31e-05	0.000134	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	1.3e-05	0.000133	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—CYP4B1—urinary bladder cancer	1.3e-05	0.000132	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	1.29e-05	0.000131	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—NAT1—urinary bladder cancer	1.29e-05	0.000131	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—GSTT1—urinary bladder cancer	1.28e-05	0.00013	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	1.27e-05	0.00013	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.27e-05	0.000129	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.26e-05	0.000128	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—IFNA2—urinary bladder cancer	1.23e-05	0.000126	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	1.23e-05	0.000126	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—SLC19A1—urinary bladder cancer	1.22e-05	0.000125	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	1.2e-05	0.000122	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PRSS3—urinary bladder cancer	1.19e-05	0.000122	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	1.18e-05	0.00012	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—RRM2—urinary bladder cancer	1.16e-05	0.000118	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—PTEN—urinary bladder cancer	1.15e-05	0.000117	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—EP300—urinary bladder cancer	1.1e-05	0.000112	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—HPGDS—urinary bladder cancer	1.07e-05	0.00011	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—ENO2—urinary bladder cancer	1.07e-05	0.00011	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.07e-05	0.000109	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	1.06e-05	0.000109	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—NQO1—urinary bladder cancer	1.06e-05	0.000108	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	1.06e-05	0.000108	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—GSTT1—urinary bladder cancer	1.04e-05	0.000106	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.03e-05	0.000105	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.02e-05	0.000105	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	1e-05	0.000102	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	9.76e-06	9.96e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	9.61e-06	9.82e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—TYMP—urinary bladder cancer	9.58e-06	9.79e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	9.56e-06	9.76e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—TYMP—urinary bladder cancer	9.53e-06	9.73e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	9.29e-06	9.48e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	9.21e-06	9.4e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	9.15e-06	9.35e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.98e-06	9.17e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	8.96e-06	9.15e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—GSTP1—urinary bladder cancer	8.85e-06	9.03e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—PLAU—urinary bladder cancer	8.76e-06	8.95e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—NAT2—urinary bladder cancer	8.67e-06	8.85e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—NQO1—urinary bladder cancer	8.65e-06	8.83e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—NAT2—urinary bladder cancer	8.62e-06	8.8e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.56e-06	8.74e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	8.49e-06	8.67e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—NAT1—urinary bladder cancer	8.49e-06	8.67e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.39e-06	8.57e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—TYMS—urinary bladder cancer	8.22e-06	8.4e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—NCOR1—urinary bladder cancer	8.13e-06	8.3e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—GSTM1—urinary bladder cancer	8.13e-06	8.3e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.82e-06	7.99e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—TYMP—urinary bladder cancer	7.8e-06	7.97e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—GPX1—urinary bladder cancer	7.79e-06	7.95e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	7.77e-06	7.93e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—ERCC2—urinary bladder cancer	7.64e-06	7.81e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.49e-06	7.65e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—RRM2—urinary bladder cancer	7.48e-06	7.64e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—RRM2—urinary bladder cancer	7.44e-06	7.6e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.32e-06	7.47e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—CREBBP—urinary bladder cancer	7.23e-06	7.38e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—GSTP1—urinary bladder cancer	7.21e-06	7.37e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—MTHFR—urinary bladder cancer	7.19e-06	7.34e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—IGF1—urinary bladder cancer	7.14e-06	7.29e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—NAT2—urinary bladder cancer	7.05e-06	7.2e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	6.99e-06	7.14e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.98e-06	7.13e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	6.93e-06	7.08e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—ENO2—urinary bladder cancer	6.93e-06	7.08e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—ENO2—urinary bladder cancer	6.89e-06	7.04e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—HPGDS—urinary bladder cancer	6.89e-06	7.04e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.89e-06	7.04e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.85e-06	7e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	6.72e-06	6.86e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—TYMS—urinary bladder cancer	6.7e-06	6.85e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GSTT1—urinary bladder cancer	6.68e-06	6.82e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—NCOR1—urinary bladder cancer	6.63e-06	6.77e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—GSTM1—urinary bladder cancer	6.63e-06	6.77e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.62e-06	6.76e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	6.6e-06	6.74e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.58e-06	6.72e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—RHOA—urinary bladder cancer	6.54e-06	6.68e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	6.44e-06	6.57e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—GPX1—urinary bladder cancer	6.35e-06	6.48e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.26e-06	6.39e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—ERCC2—urinary bladder cancer	6.23e-06	6.36e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—RRM2—urinary bladder cancer	6.09e-06	6.22e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—MTHFR—urinary bladder cancer	5.86e-06	5.98e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PPARG—urinary bladder cancer	5.83e-06	5.95e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—ENO2—urinary bladder cancer	5.64e-06	5.76e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	5.64e-06	5.76e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.61e-06	5.73e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—CREBBP—urinary bladder cancer	5.6e-06	5.72e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—NQO1—urinary bladder cancer	5.59e-06	5.7e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—NQO1—urinary bladder cancer	5.55e-06	5.67e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—IL2—urinary bladder cancer	5.49e-06	5.6e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	5.47e-06	5.59e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.42e-06	5.53e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.39e-06	5.5e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.39e-06	5.5e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—TYMP—urinary bladder cancer	5.14e-06	5.25e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—EP300—urinary bladder cancer	4.92e-06	5.03e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—SRC—urinary bladder cancer	4.79e-06	4.89e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PPARG—urinary bladder cancer	4.75e-06	4.85e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.73e-06	4.83e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.7e-06	4.8e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	4.66e-06	4.76e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.65e-06	4.75e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GSTP1—urinary bladder cancer	4.63e-06	4.73e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PTGS2—urinary bladder cancer	4.58e-06	4.68e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—CREBBP—urinary bladder cancer	4.56e-06	4.66e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—NQO1—urinary bladder cancer	4.55e-06	4.64e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.51e-06	4.6e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.48e-06	4.58e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.41e-06	4.5e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—TYMS—urinary bladder cancer	4.33e-06	4.42e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—TYMS—urinary bladder cancer	4.31e-06	4.4e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	4.28e-06	4.37e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	4.28e-06	4.37e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GSTM1—urinary bladder cancer	4.26e-06	4.35e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—NCOR1—urinary bladder cancer	4.26e-06	4.35e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GPX1—urinary bladder cancer	4.1e-06	4.19e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GPX1—urinary bladder cancer	4.08e-06	4.16e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	4.03e-06	4.11e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—RRM2—urinary bladder cancer	4.02e-06	4.1e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—ERCC2—urinary bladder cancer	4e-06	4.09e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PTEN—urinary bladder cancer	4e-06	4.08e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—KRAS—urinary bladder cancer	3.96e-06	4.05e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.85e-06	3.93e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—EP300—urinary bladder cancer	3.81e-06	3.89e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	3.79e-06	3.87e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	3.78e-06	3.86e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—MTHFR—urinary bladder cancer	3.76e-06	3.84e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PTGS2—urinary bladder cancer	3.74e-06	3.82e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.72e-06	3.8e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.72e-06	3.8e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.67e-06	3.75e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.61e-06	3.68e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—TYMS—urinary bladder cancer	3.52e-06	3.6e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—TP53—urinary bladder cancer	3.52e-06	3.6e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	3.48e-06	3.56e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	3.48e-06	3.56e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—HRAS—urinary bladder cancer	3.37e-06	3.44e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GPX1—urinary bladder cancer	3.34e-06	3.41e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	3.28e-06	3.35e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PTEN—urinary bladder cancer	3.26e-06	3.33e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—EP300—urinary bladder cancer	3.11e-06	3.17e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	3.08e-06	3.14e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PPARG—urinary bladder cancer	3.07e-06	3.13e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PPARG—urinary bladder cancer	3.05e-06	3.12e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3e-06	3.06e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	2.95e-06	3.01e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—CREBBP—urinary bladder cancer	2.93e-06	2.99e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.5e-06	2.55e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.5e-06	2.55e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	2.41e-06	2.46e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PTGS2—urinary bladder cancer	2.4e-06	2.45e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	2.4e-06	2.45e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.32e-06	2.37e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.3e-06	2.35e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.3e-06	2.35e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.2e-06	2.25e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.16e-06	2.21e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PTEN—urinary bladder cancer	2.1e-06	2.15e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PTEN—urinary bladder cancer	2.09e-06	2.14e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.03e-06	2.07e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—EP300—urinary bladder cancer	2.01e-06	2.05e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—EP300—urinary bladder cancer	2e-06	2.04e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.96e-06	2.01e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.71e-06	1.75e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.65e-06	1.68e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.63e-06	1.67e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.58e-06	1.62e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.3e-06	1.32e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.13e-06	1.15e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.08e-06	1.1e-05	CbGpPWpGaD
